Last reviewed · How we verify
NCT04008524
A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies
trial testing CAR-T cells in Relapsed and Refractory Hematological Malignancies. Available.
Quick facts
| Lead sponsor | Institute of Hematology & Blood Diseases Hospital, China |
|---|---|
| Status | AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 1 location across China |
Drugs / interventions tested
- CAR-T cells
Conditions studied
- Relapsed and Refractory Hematological Malignancies — all drugs for Relapsed and Refractory Hematological Malignancies →
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Who can join
Eligibility, any sex, with Relapsed and Refractory Hematological Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project is intended to provide CAR-T cell therapy products for patients with severely life-threatening relapsed and refractory hematological malignancies. These patients have been previously treated sufficiently, currently have no other treatment methods available, and do not meet the inclusion criteria of other clinical trial projects in the process of subject recruitment or meet their exclusion criteria. This project is designed to meet the urgent clinical needs of individual patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04008524
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CAR-T cells
Trials testing the same drug.
- NCT06481228 — Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL · NA · recruiting
- NCT06429150 — Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma · Phase 1, PHASE2 · recruiting
- NCT06352281 — Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP) · Phase 1, PHASE2 · recruiting
- NCT05779917 — Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers · Phase 1 · recruiting
- NCT05420493 — Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Ly · Phase 1 · unknown
Other Institute of Hematology & Blood Diseases Hospital, China trials
Trials by the same sponsor.
- NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
- NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
- NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
- NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
- NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04008524 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
- Last refreshed: 6 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04008524.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing